

Fall 11-4-2015

# Protein Refinery Operations Lab (PRO Lab): A sandbox for continuous protein production & advanced process control

Mark Brower

*Merck & Co., Inc*, [mark.brower@merck.com](mailto:mark.brower@merck.com)

David Pollard

*Merck & Co., Inc*

Finn Hung

*Merck & Co., Inc*

Follow this and additional works at: [http://dc.engconfintl.org/biomanufact\\_ii](http://dc.engconfintl.org/biomanufact_ii)

 Part of the [Biomedical Engineering and Bioengineering Commons](#)

---

## Recommended Citation

Mark Brower, David Pollard, and Finn Hung, "Protein Refinery Operations Lab (PRO Lab): A sandbox for continuous protein production & advanced process control" in "Integrated Continuous Biomanufacturing II", Chetan Goudar, Amgen Inc. Suzanne Farid, University College London Christopher Hwang, Genzyme-Sanofi Karol Lacki, Novo Nordisk Eds, ECI Symposium Series, (2015). [http://dc.engconfintl.org/biomanufact\\_ii/82](http://dc.engconfintl.org/biomanufact_ii/82)

This Conference Proceeding is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Integrated Continuous Biomanufacturing II by an authorized administrator of ECI Digital Archives. For more information, please contact [franco@bepress.com](mailto:franco@bepress.com).

# Protein Refinery Operations Lab (PRO Lab): A sandbox for continuous protein production & advanced process control




**Mark Brower**

BioProcess Development  
Merck Research Labs  
Merck & Co. Inc  
Kenilworth, NJ

ECI Integrated Continuous Biomanufacturing II  
Berkeley, CA  
01-05 November 2015



# Merck's Motivation





- Merck lags other major biopharma companies on installed SS bioreactor capacity\*
- Can this “disadvantage” be leveraged into a competitive advantage?

\* Source: BioPlan 10<sup>th</sup> Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

# Facility of the Future

## CHO mAb Processing Vision at Merck



### Adaptive Process Control

PAT tools

Predictive MDVA models

Real Time Release Testing

### Equipment Performance Real time Monitoring

Examples:

- Real time sensing of Pump seal failure, PAT sensor performance
- Proactive preventative maintenance to limit failures
- Eqpt redundancy strategy
- Process flow strategy for deviations

**THE P-F CURVE**

Performance vs Time

Monitoring points: P - Start of Failure, Oil Analysis, Thermography, Vibration - Human Touch, Audible - Human Hearing, Temperature - Human Touch, F - Catastrophic Failure.

Be well


### SU operations

Automated Inventory management

Single use Workflows  
Buffer supply  
Fluid flow management



# A Sandbox for the Facility of Future

## *Protein Refinery Operations (PRO Lab)*



- PAT & sampling integration
- Process monitoring and MVDA modeling
- Adaptive/feedback unit operation control
- Robust control strategies
  
- Connections and piping
- Component engineering
- Component change-outs (filters etc.)
- Liquid and RM management
  
- Medium-scale operation
- PAT & control implementation
- Batch demonstrations
- Applying facility of the future principles
  
- Robust manufacturing platform

# PRO Lab Timeline



B#1  
40 Days  
Debugging

B#2  
50-70 Days  
(On-Going)

MVDA Modeling  
& Perturbation Analysis



\$ Define Base Control Strategies  
& Order Components

\$ Order & Install  
Components




# PRO Lab:

## Fully automated mAb drug substance



- Distributed control for all unit ops
- Overview & unit-ops level views

# PRO Lab Layout





- Upstream area for perfusion bioreactor
- Downstream unit operations in connected “U” shape
- Routine operations at 10L bioreactor
- Analytical hub
- Buffer/media holds outside of process area
- Hardware agnostic



# Operating Principles


## *A Lights-Out Approach*



- Each unit operation represented
- Surge vessels used to collect and feed next unit operation
- Stream adjustments & sampling in surge vessels
- Redundant filters
- Speed compensated methods with breakpoints
- SU/closed processing methodology



# Upstream Perfusion Operations





- Routine operation at 10L scale
- 50L scale-up demonstrations
- SU AutoTFF cell retention device
- Weldable filter replacements



# Upstream Operation Performance

## Cell Culture Operation



### Baseline Perfusion Performance


- Stable cell density
- Viability maintained >99%
- Productivities > 1g/(L·Day)
- Membrane fouling and antibody sieving
- Significant cell lysis

### Capacitance Measurement

- Capacitance for “in-vivo” biomass monitoring
- Correlation of online and offline biomass measurement
- Used to automate cell bleed and maintain constant biomass


# Downstream Operations

## *Protein A Chromatography*



### Protein A Chromatography


- Predictable reproducible elution
- Low feed pressure
- Accelerated column lifetime



### Systems Closure


- Guard Filter Performance
  - 1 Guard filter per day → 1 guard filter per batch
  - Volume based filter switching

# Automated Sample Collection & Analysis



## In-tank clarification


- Ceramic membrane sampling device
- Automated sample management
- Integration with 3<sup>rd</sup> party analytics
- Sieving of product with surface fouling



## External clarification

- Sanitized sample port
- Cell removal device
- Automated sample management & integration with 3<sup>rd</sup> party analytics
- Hybrid solution targeted January 2016

# Continuous Processing: PAT, Automated Control & Real Time Release



- End Product Testing transition to Real Time Release Testing
- Real time automated control: process responds to variability & disturbances
  - End to end prediction models for complete process
  - RM control → Process input → Product quality & yield

# Multi Attribute Method via Peptide Mapping

“Direct measurement of CQA’s at molecular level”


Quality Attribute	Current Method
Identity	Immunoassay
Glycans	HILIC-Fluor
Charge Variants	CEX-HPLC
Oxidation	HIC
Clips	rCE-SDS
Process Impurities	HCP/ProA ELISA

➔ **MAM  
Peptide Mapping**



Thermo Q-Exactive LC-MS

Characterization



30 minute  
Digest


LC-MS/MS



Search  
Algorithm



LC-MS TIC



Monitoring



LC-MS1 only



Targeted and  
untargeted peak  
detection




Compliant method





30 min Tryptic digest—Ren, D. et. al. Anal Biochem. 2009 Sep 1;392(1):12-21  
MAM—Rogers, R. S. et. al. mAbs 2015 Sep 3;7(5):881-90



# PAT UPLC Process Monitoring



## Perfusion profile monitoring (SEC)




- SEC quality and permeate monitoring
- Water soluble vitamins with QDA MS Detector
- Multi-attribute peptide mapping methods installation in 1Q 2016




# Continuous Process Performance

## Perturbation Analysis






*Upon reaching steady state, purity and quality attributes remain consistent*



● Main Peak    ◆ Acidic Variants    ▲ Basic Variants

- More complex perturbation analysis expected with MAM method
- Predicting outcomes from indicator process intermediates



# Conclusions

- A fully automated continuous bioprocessing suite has been established at Merck with distributed control via DeltaV
- The facility has been designed using “lights out” and closed processing approaches
- Two perfusion batches have been demonstrated in the lab to date achieving steady state cell densities for >50 days
- PRO Lab will serve as a sandbox for new sampling, PAT and MVDA strategies with ultimate feedback and adaptive control

# Acknowledgements



- Adrian Gospodarek
- Finn Hung
- Christopher Kistler
- William Napoli
- Nuno Pinto
- Doug Richardson
- David Roush
- Nihal Tugcu



- Marc Bisschops
- Stephen Allen
- Lynne Frick



- Maury Bayer
- Edgar Rivera